Clinical Trials
6
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 3
1 (16.7%)A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: HP568 in combination with palbociclib
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06757335
A Phase I/II Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: HP518 - Dose EscalationDrug: HP518 -Dose Expansion
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06155084
- Locations
- 🇨🇳
The Second Hospital Of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT03851640
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03778047
- Locations
- 🇨🇳
Medical Ethics Committee of Hunan Cancer Hospital, Changsha, China
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03776968
- Locations
- 🇨🇳
Shanghai Changhai Hospital Ethics Committee, Shanghai, China
- Prev
- 1
- 2
- Next
News
No news found